Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of July 2019, with a specific reporting date of July 15, 2019. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs).
Key Financial Metrics
This filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It strictly reports on specific share transactions.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.2563 per share.
- Transaction Volume: 23 shares (Mr. D S Redfern) and 20 shares (Mrs. V A Whyte).
- Transaction Date: July 12, 2019.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing reports no material changes to the company's financial position or operations. The only changes noted are the minor increases in shareholdings for two specific executives resulting from dividend reinvestment plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions described were acquisitions of ordinary shares following the reinvestment of dividends paid to shareholders on July 11, 2019, on shares held within an Individual Savings Account (ISA).
Key Facts for Investor Verification
- Verify the dividend reinvestment plan terms applicable to the July 11, 2019 dividend payment.
- Confirm the share price of £16.2563 on the London Stock Exchange for July 12, 2019.
- Note that the transactions involved minimal volumes (23 and 20 shares) and do not reflect significant insider trading activity or changes in executive sentiment.
- Recognize that this document provides no data on GSK's overall financial performance for the period.